Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390611 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT00390611 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 85 participants.
The verdict
NCT00390611, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
This trial will compare the efficacy and toxicity of standard first-line chemotherapy alone vs. standard chemotherapy plus sorafenib in patients with stage III/IV ovarian cancer following cytoreductive surgery. Patients with residual large volume disease and/or bowel involvement will be excluded, to minimize the risk of bowel perforation.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2006-10 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390611
The ClinicalTrials.gov registry entry for NCT00390611 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00390611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00390611 about?
NCT00390611 is a clinical study titled "Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer". This trial will compare the efficacy and toxicity of standard first-line chemotherapy alone vs. standard chemotherapy plus sorafenib in patients with stage III/IV ovarian cancer following cytoreductive surgery. Patients with residual large volume disease and/or bowel involvement will be excluded, to...
What is the current status of trial NCT00390611?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2006-10. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00390611?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00390611?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.